

Speaker's Biosketch

ICoLA 2024

Judy de Haan (Baker Heart and Diabetes Institute, Australia)

Prof Judy de Haan is Head of the Cardiovascular Inflammation and Redox Biology Laboratory at the Baker Heart and Diabetes Institute, Melbourne, Australia. Prof de Haan is President of the Australian Atherosclerosis Society (AAS, 2023-2025) and an appointed member of the Australian Cardiovascular Alliance (ACvA) Drug Discovery and Translation Flagship. She also serves on the AAS Scientific Organizing Committee. Prof de Haan is internationally recognized as a leader in the field of redox biology. She has developed several novel redox-based therapeutic strategies for the protection against diabetic end-organ damage, particularly for the diabetic eye, kidneys and the vasculature. This stems from her understanding of the oxidative and pro-inflammatory mechanisms that drive diabetic micro- and macrovascular complications. More recently, her interests have extended to the design of novel stent coatings to limit diabetes-associated in-stent restenosis. Her research output includes 95+ publications (>5800 citations, H-index: 43) in top-ranked journals such as *Circulation* and *Diabetes*. Her work has been supported by competitive grants from the Australian government (NHMRC 2024-2027), the Australian Heart Foundation, Diabetes Australia, and Industry (Bayer, Reata Pharma). In today's presentation Prof de Haan will overview various novel redox and anti-inflammatory approaches to improve diabetes-driven cardiovascular diseases in preclinical mouse models.